BiotechTube
Home/Kalbe/Dr. Hary Tanoesoedibjo
DH

Dr. Hary Tanoesoedibjo

President Director & CEO

Kalbe

Therapeutic Areas

OncologyImmunologyCardiovascularMetabolismInfectious Diseases

Kalbe Pipeline

DrugIndicationPhase
K‑001Non‑small cell lung cancerPhase 3
K‑202Rheumatoid arthritisPhase 2
K‑303Various solid tumors (bevacizumab biosimilar)Phase 3

Leadership Team at Kalbe

DR
Dr. R. H. Siregar
Chief Scientific Officer
View full Kalbe profile